Impact of Etanercept on Vitamin D Status and Vitamin D-binding Protein in Bio-naive Patients with Psoriasis

High levels of serum vitamin D-binding protein have been shown previously in patients with psoriasis compared with healthy controls; a possible role in inflammation is implied. The primary objective of this study was to investigate the impact of 24-week etanercept treatment on vitamin D status and vitamin D-binding protein in patients with psoriasis. The secondary aim was to explore whether pre-treatment vitamin D levels could predict the treatment effect. A prospective observational study was performed, including 20 patients with psoriasis and 15 controls. Serum samples were analyzed for, among others, vitamin D metabolites, vitamin D-binding protein and highly sensitive C-reactive protein. Baseline levels of vitamin D-binding protein were higher in patients with self-reported arthropathy than in those without. After 24 weeks' treatment, an improvement in psoriasis was noted, as was a decrease in highly sensitive C-reactive protein. Vitamin D-binding protein decreased in those with self-reported arthropathy. Higher baseline levels of vitamin D were associated with faster and greater improvement in psoriasis. Vitamin D-binding protein may have an inflammatory biomarker role.

Automated summary

Higher levels of serum vitamin D-binding protein have been found in patients with psoriasis compared to healthy controls, suggesting a potential role in inflammation. Treatment with etanercept for 24 weeks resulted in improvements in psoriasis and a decrease in highly sensitive C-reactive protein levels. Higher baseline levels of vitamin D were associated with faster and greater improvement in psoriasis, indicating a potential predictive value for treatment outcomes.